FMP
Soleno Therapeutics, Inc.
SLNO
NASDAQ
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
45.18 USD
-0.02 (-0.04427%)
About
ceo
Dr. Anish Bhatnagar M.D.
sector
Healthcare
industry
Biotechnology
website
https://soleno.lifeexchange
NASDAQ
Description
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
CIK
0001484565
ISIN
US8342033094
CUSIP
834203200
Address
203 Redwood Shores Parkway
Phone
650 213 8444
Country
US
Employee
33
IPO Date
Nov 13, 2014
Key Executives
